Home > PJ > Leading article

Return to PJ Online Home Page

The Pharmaceutical Journal Vol 267 No 7178 p838
15 December 2001

This article
Reprint
Photocopy

Leading Article


Bitter pills

Anger and disappointment over the Government's handling of pharmacists' remuneration spread to the Council of the Royal Pharmaceutical Society last week. A motion proposed that the President should seek immediate discussion with the chief executive and chairman of the Pharmaceutical Services Negotiating Committee with a view to a supportive, professionally based, joint approach to the Secretary of State for Health to ensure that account is taken of the profession's views. After a lengthy debate, which in the main was not controversial, the motion was carried (p871).

The strongest case came from Digby Emson who was concerned that the huge increase in volume of prescriptions currently dispensed could have serious consequences for patient safety and was counter to the Government's own espousal of the principles of clinical governance.

However, many of the other points made, although acknowledging the role of the PSNC as the body that had responsibility for remuneration and other commercial considerations, seemed to suggest that in this instance, the President should also take up the financial cudgels.

It must not be forgotten that the Royal Pharmaceutical Society is not a trade union or membership organisation (like the British Medical Association) but a regulatory body with a remit for professional standard setting (a cross between the General Medical Council and the Royal colleges). And although patient safety is well within its remit, remuneration is not.

It took two of the three Privy Council-nominated members of the Council to remind their colleagues that this type of debate would not be deemed suitable for the GMC and the Council should be careful about the basis on which it supports the work of the PSNC.

This will be a bitter pill to swallow for many community pharmacists who still view the Society as a membership organisation.

But there will also come a time when it could be a bitter pill for some Council members to swallow. The Privy Council nominees are the independent voice on Council. At the moment they constitute a small minority. When the Council is reconstituted — which it will have to be, in order to fulfil the Government's requirements of a modern regulatory body — that small independent minority will rise to 40 to 50 per cent of the Council membership. If nothing else, that independent voice will sharpen the Society's and the Council's view of its remit and ensure that it does not stray into others' territories.

Back to Top


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal